Gilead Sciences GILD NASDAQ:GILD

Healthcare Losers: Bristol-Myers Squibb (NYSE:BMY), LDR Holding Corp (NASDAQ:LDRH), Vanda Pharmaceuticals (NASDAQ:VNDA), Infinity Pharmaceuticals Inc. (NASDAQ:INFI)

Bristol-Myers Squibb Co (NYSE:BMY) and Urban Outfitters (URBN) retreated 6.1 percent and 3.6 percent respectively, after brokers lowered their ratings on these stocks. Weaker-than-expected first-quarter results and dismal second-quarter earnings guidance led Wal-Mart Stores (WMT) to drop 2.4 per cent. Bristol-Myers Squibb Co (NYSE:BMY) stock performance was -6.12% in last session and finished the day at $48.93. Traded volume was 28.56million shares in the last session and the average volume of the stock remained 8.31million shares. The beta of the stock remained 0.48. Bristol-Myers Squibb Co (NYSE:BMY) insider ownership is 0.10%.

LDR Holding Corporation (NASDAQ:LDRH), a global medical device company focused on designing and commercializing novel and proprietary spinal surgical technologies, announced the pricing of a follow-on offering of 3,972,089 shares of its common stock at a price of $24.50, before underwriting discounts. LDR Holding Corporation (NASDAQ:LDRH) is selling 1,300,000 shares of common stock in the offering and certain existing stockholders are selling 2,672,089 shares of common stock in the offering. In addition, the Company has granted the underwriters a 30-day option to purchase up to 195,000 additional shares of common stock, and the selling stockholders have granted the underwriters a 30-day option to purchase up to 400,813 additional shares of common stock. The Company will not receive any of the proceeds from the sale of shares sold by the selling stockholders. LDR Holding Corp (NASDAQ:LDRH) dropped -5.86 percent to $23.29 Thursday on volume of 1.63million shares. The intra-day range of the stock was $23.06 to $24.75. LDR Holding Corp (NASDAQ:LDRH) has a market capitalization of $563.34million.

Vanda Pharmaceuticals Inc (NASDAQ:VNDA) issued its quarterly earnings data on Thursday. The company reported ($0.79) EPS for the quarter, missing the Thomson Reutersconsensus estimate of ($0.29) by $0.50, Analyst Ratings News reports. The company had revenue of $9.10 million for the quarter, compared to the consensus estimate of $8.50 million. Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)’s stock on May 15, 2014 reported a decrease of -6.01% to the closing price of $9.86. Its fifty two weeks range is $5.37 -$19.25. The total market capitalization recorded $333.92million. The overall volume in the last trading session was 1.05million shares. In its share capital, VNDA has 33.87million outstanding shares.

Infinity Pharmaceuticals Inc. (NASDAQ:INFI) had its “overweight” rating reaffirmed by analysts at JPMorgan Chase & Co.. They now have a $20.00 price target on the stock, down previously from $24.00. On Thursday, shares of Infinity Pharmaceuticals Inc. (NASDAQ:INFI) dropped -5.10% to close the day at $9.11. Company monthly performance is recorded as -6.95%. Infinity Pharmaceuticals Inc. (NASDAQ:INFI) quarterly revenue growth is -31.91%.